Amkay Products IPO: Amkay Products IPO open on April 30, 2024 and closes on May 3, 2024. The IPO will list on BSE SME with tentative listing date fixed as Wednesday, May 8, 2024.
Amkay Products IPO Details:
| IPO Date | April 30, 2024 to May 3, 2024 |
| Face Value | Rs 10 per share |
| Price Band | Rs 52 to Rs 55 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 2,292,000 shares (aggregating up to Rs 12.61 Cr) |
| Fresh Issue | 2,292,000 shares (aggregating up to Rs 12.61 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE SME |
| Share holding pre issue | 6,363,640 |
| Share holding post issue | 8,655,640 |
| Market Maker portion | 120,000 shares |
Amkay Products IPO Price:
Amkay Products IPO is fixed price set at Rs 52 to Rs 55 per share.
Amkay Products IPO Subscription Status:
The Amkay Products IPO opened for subscription on April 30, 2024 and will close on May 3, 2024.
Amkay Products IPO GMP:
Amkay Products IPO GMP is Rs 25, with the price band of 55.00.
Amkay Products IPO Lot Size:
Amkay Products IPO minimum lot size is 2000 Shares. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to Rs 220,000.
Amkay Products IPO Allotment Status:
The Amkay Products IPO is expected to be finalized on Monday, May 6, 2024. The IPO will list on BSE SME with tentative listing date fixed as Wednesday, May 8, 2024.
Amkay Products IPO Listing Date:
The Amkay Products IPO opens on April 30, 2024, and closes on May 3, 2024.
| IPO Open Date | Tuesday, April 30, 2024 |
| IPO Close Date | Friday, May 3, 2024 |
| Basis of Allotment | Monday, May 6, 2024 |
| Initiation of Refunds | Tuesday, May 7, 2024 |
| Credit of Shares to Demat | Tuesday, May 7, 2024 |
| Listing Date | Wednesday, May 8, 2024 |
Amkay Products IPO Promoter Holding:
The Promoters of the Amkay Products company are Kashyap Pravin Mody and Himanshu Kantilal Batavia.
Amkay Products IPO Review:
Dilip Davda – The company is in medical device segment, which is not only overcrowded, but also on the verge of saturation point. It’s a highly competitive and fragmented segment post covid. Based on FY24 annualized earnings, the issue is fully priced discounting all near term positives. Well-informed/cash surplus investors may park moderate funds for the medium to long term rewards.
Amkay Products IPO Buy or Not:
- Brokers: Subscribe 1
- Members: Subscribe 0
• Disclaimer: The above article is meant for informational purposes only, any investment stock market & mutual fund please advice financial expert.
Khobar Time: Read the latest Technology news, Finance, Entertainment, Business updates, Automobiles news here. So, stay connected with us to get daily news.